Kausik Ray: Efficacy and Safety of Obicetrapib in Patients With HeFH on Maximally Tolerated Statins
Kausik Ray, Professor of Public Health at Imperial College London, Past President of European Atherosclerosis Society, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
”Our key publication on the efficacy and safety of obicetrapib in patients with HeFH on maximally tolerated statins published in Nature Medicine. Well done, Stephen Nicholls.
Obicetrapib reduced LDL-C by ~ 36%, resulting in more patients achieving risk-based LDL-C goals and reduced Lp (a) meaningfully.
The ultimate test of this novel approach, CETPi, will come from PREVAIL.
Why it matters….. As we have shown (Hu et al., Circulation) HeFH occurs in 1:311 people globally. Our FHSC (Lancet 2021) showed globally the average age of diagnosis is 44 years, with less than 2% adults identified before the age of 18. This means that at detection, because of missed years of cholesterol exposure, 17% already have cardiovascular disease. Hence, we need to claw those years back with combination therapies. Only 2% of patients were at goal in the FHSC 2021 paper globally; we need effective, affordable treatments.
With obicetrapib expected in 2026 in Europe, we will have another tool in our arsenal to manage patients with HeFH.”
Title: Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial
Authors: Stephen J. Nicholls, Adam J. Nelson, Marc Ditmarsch, John J. P. Kastelein, Christie M. Ballantyne, Kausik K. Ray, Ann Marie Navar, Steven E. Nissen, Anne C. Goldberg, Liam R. Brunham, Erin Wuerdeman, Annie L. Neild, Douglas Kling, Andrew Hsieh, Julie Butters, Brian A. Ference, Ulrich Laufs, Maciej Banach, Roxana Mehran, Alberico L. Catapano, Michael Szarek, Violeta Balinskaite, Michael H. Davidson
Read the Full Article on Nature Medicine
Stay updated with Hemostasis Today.
-
Sep 23, 2026, 03:27Abbie Newton: How Better Data Can Reduce Platelet Wastage
-
Sep 23, 2026, 03:01Suvro Sankha Datta: Rapid Blood Group Genotyping Using Gold Oligo Nanonet Assembly
-
Sep 23, 2026, 02:55Asghar Muhammad: Exploring New Ways to Expand Blood Transfusion Compatibility
-
Sep 23, 2026, 02:49Bianca Rocca: Personalized Cardiovascular Pharmacotherapy in the September 2026 EHJ Issue
-
Sep 23, 2026, 02:35Udaya RajBhandari: A Hidden Risk of Repeated Transfusions in β Thalassemia
-
Sep 23, 2026, 00:08Janar Sathananthan: The Importance of Durable Drug Delivery in DCB Therapy
-
Sep 23, 2026, 00:07Arun V J: How Does a Good Conference Destroy My Ego?
-
Sep 23, 2026, 00:06Akshat Jain: Sickle Cell Disease Is Not One Size Fits All
-
Sep 23, 2026, 00:05Sherri Ozawa: Nicole De Vita’s Iron Deficiency Infographic Recognized at SABM